
Retatrutide (RT3-GLP) 10mg
Triple receptor agonist studied in clinical research on GLP-1, GIP, and glucagon pathway modulation.
In Stock
SKU: ML-RETA-10MG
💰 Volume Discounts:
Buy 3+ vials = 10% off · Buy 5+ vials = 15% off
Retatrutide is an investigational triple receptor agonist that activates GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors simultaneously. Published Phase II clinical research (New England Journal of Medicine, 2023) has investigated its effects on body weight, metabolic markers, and adipose tissue in controlled trial populations. Retatrutide is currently in clinical development and is not approved as a medication by the FDA or other regulatory bodies. For in-vitro and laboratory research use only.
Related Products

AOD9604 5mg
Growth hormone fragment for targeted fat reduction — stimulates lipolysis and inhibits lipogenesis without affecting blood sugar or growth.

Retatrutide (RT3-GLP) 20mg
Triple receptor agonist (GLP-1/GIP/glucagon) — 20mg vial offers a lower cost per mg than the 10mg vial.

MOTS-C 40mg
Mitochondrial exercise mimetic — AMPK activation, insulin sensitivity, and fat metabolism. Larger dose vial for extended protocols.

Tirzepatide 10mg
Dual GLP-1/GIP receptor agonist — up to 22.5% body weight reduction in trials, the most effective approved weight loss compound to date.